Cargando…

Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study

Sodium‐glucose cotransporter 2 (SGLT2) inhibitors reduce the occurrence of cardiovascular and renal complications in patients with type 2 diabetes mellitus (T2DM) and represent guideline‐recommended therapy in this indication. However, precise mechanisms underlying the beneficial cardiovascular effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kario, Kazuomi, Okada, Kenta, Murata, Mitsunobu, Suzuki, Daisuke, Yamagiwa, Kayo, Abe, Yasuhisa, Usui, Isao, Tsuchiya, Norihiro, Iwashita, Chie, Harada, Noriko, Okawara, Yukie, Ishibashi, Shun, Hoshide, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590106/
https://www.ncbi.nlm.nih.gov/pubmed/32810338
http://dx.doi.org/10.1111/jch.13988
_version_ 1783600731652096000
author Kario, Kazuomi
Okada, Kenta
Murata, Mitsunobu
Suzuki, Daisuke
Yamagiwa, Kayo
Abe, Yasuhisa
Usui, Isao
Tsuchiya, Norihiro
Iwashita, Chie
Harada, Noriko
Okawara, Yukie
Ishibashi, Shun
Hoshide, Satoshi
author_facet Kario, Kazuomi
Okada, Kenta
Murata, Mitsunobu
Suzuki, Daisuke
Yamagiwa, Kayo
Abe, Yasuhisa
Usui, Isao
Tsuchiya, Norihiro
Iwashita, Chie
Harada, Noriko
Okawara, Yukie
Ishibashi, Shun
Hoshide, Satoshi
author_sort Kario, Kazuomi
collection PubMed
description Sodium‐glucose cotransporter 2 (SGLT2) inhibitors reduce the occurrence of cardiovascular and renal complications in patients with type 2 diabetes mellitus (T2DM) and represent guideline‐recommended therapy in this indication. However, precise mechanisms underlying the beneficial cardiovascular effects of SGLT2 inhibitors are not fully understood. This study investigated the effects of the SGLT2 inhibitor, luseogliflozin, on arterial properties and home blood pressure (BP) in patients with T2DM. This multicenter, single‐arm study enrolled adults with T2DM, glycosylated hemoglobin (HbA1c) 6.5%‐8.9% in the previous 4 weeks, and an indication for new/additional antidiabetic therapy. Luseogliflozin 2.5 mg/d was given for 12 weeks. Primary outcome was change in cardio‐ankle vascular index (CAVI) from baseline to Week 4 and Week 12. Home and office BP, BP variability, and metabolic parameters were secondary endpoints. Forty‐seven patients (mean age 63.5 ± 10.7 years) treated with luseogliflozin were included in the full analysis set. CAVI did not change significantly from baseline (mean [95% confidence interval] 8.67 [8.37‐8.97]) to Week 12 (8.64 [8.38‐8.91]; P = .750), but there were significant reductions from baseline in morning home BP, HbA1c, body weight, body mass index, and serum uric acid levels during luseogliflozin therapy. The reduction in morning home systolic BP was ≥ 5 mm Hg and was independent of baseline BP and BP control status. In conclusion, there was no change in arterial stiffness (based on CAVI) during treatment with luseogliflozin, but changes in BP and metabolic parameters were consistent with the known beneficial effects of SGLT2 inhibitors in T2DM.
format Online
Article
Text
id pubmed-7590106
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75901062020-10-30 Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study Kario, Kazuomi Okada, Kenta Murata, Mitsunobu Suzuki, Daisuke Yamagiwa, Kayo Abe, Yasuhisa Usui, Isao Tsuchiya, Norihiro Iwashita, Chie Harada, Noriko Okawara, Yukie Ishibashi, Shun Hoshide, Satoshi J Clin Hypertens (Greenwich) Sglt2 Inhibition Sodium‐glucose cotransporter 2 (SGLT2) inhibitors reduce the occurrence of cardiovascular and renal complications in patients with type 2 diabetes mellitus (T2DM) and represent guideline‐recommended therapy in this indication. However, precise mechanisms underlying the beneficial cardiovascular effects of SGLT2 inhibitors are not fully understood. This study investigated the effects of the SGLT2 inhibitor, luseogliflozin, on arterial properties and home blood pressure (BP) in patients with T2DM. This multicenter, single‐arm study enrolled adults with T2DM, glycosylated hemoglobin (HbA1c) 6.5%‐8.9% in the previous 4 weeks, and an indication for new/additional antidiabetic therapy. Luseogliflozin 2.5 mg/d was given for 12 weeks. Primary outcome was change in cardio‐ankle vascular index (CAVI) from baseline to Week 4 and Week 12. Home and office BP, BP variability, and metabolic parameters were secondary endpoints. Forty‐seven patients (mean age 63.5 ± 10.7 years) treated with luseogliflozin were included in the full analysis set. CAVI did not change significantly from baseline (mean [95% confidence interval] 8.67 [8.37‐8.97]) to Week 12 (8.64 [8.38‐8.91]; P = .750), but there were significant reductions from baseline in morning home BP, HbA1c, body weight, body mass index, and serum uric acid levels during luseogliflozin therapy. The reduction in morning home systolic BP was ≥ 5 mm Hg and was independent of baseline BP and BP control status. In conclusion, there was no change in arterial stiffness (based on CAVI) during treatment with luseogliflozin, but changes in BP and metabolic parameters were consistent with the known beneficial effects of SGLT2 inhibitors in T2DM. John Wiley and Sons Inc. 2020-08-18 /pmc/articles/PMC7590106/ /pubmed/32810338 http://dx.doi.org/10.1111/jch.13988 Text en ©2020 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Sglt2 Inhibition
Kario, Kazuomi
Okada, Kenta
Murata, Mitsunobu
Suzuki, Daisuke
Yamagiwa, Kayo
Abe, Yasuhisa
Usui, Isao
Tsuchiya, Norihiro
Iwashita, Chie
Harada, Noriko
Okawara, Yukie
Ishibashi, Shun
Hoshide, Satoshi
Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study
title Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study
title_full Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study
title_fullStr Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study
title_full_unstemmed Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study
title_short Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study
title_sort effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: the multicenter, exploratory luscar study
topic Sglt2 Inhibition
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590106/
https://www.ncbi.nlm.nih.gov/pubmed/32810338
http://dx.doi.org/10.1111/jch.13988
work_keys_str_mv AT kariokazuomi effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy
AT okadakenta effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy
AT muratamitsunobu effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy
AT suzukidaisuke effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy
AT yamagiwakayo effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy
AT abeyasuhisa effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy
AT usuiisao effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy
AT tsuchiyanorihiro effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy
AT iwashitachie effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy
AT haradanoriko effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy
AT okawarayukie effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy
AT ishibashishun effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy
AT hoshidesatoshi effectsofluseogliflozinonarterialpropertiesinpatientswithtype2diabetesmellitusthemulticenterexploratoryluscarstudy